部分中文美洛昔康处方资料（仅供参考） 美洛昔康( Meloxicam ) 化学名：4-羟基-2-甲基-N-(5-甲基-1,3-噻唑-2-基)-2H-1,2-苯并噻嗪-3-羧酸乙酯 1,1-二氧化物 类别： 美洛昔康是非甾体抗炎药，用来减轻一些关节炎的症状，治疗风湿药 适应症： 使用于类风湿性关节炎的症状治疗，疼痛性骨关节炎（关节病、退行性骨关节病）的症状治疗。 用法用量： 口服，用水或流质送服吞咽。 　　 类风湿性关节炎：每天15mg（2片），根据治疗后反应，剂量可减至一日7.5mg（1片）。 　　 骨关节炎：一日7.5mg（1片），如果需要，剂量可增值一日15mg（2片）。 　　 对于不良反应有可能增加的病人：治疗开始剂量一日7.5mg(1片)。 　　 严重肾衰竭的病人透析时：剂量不应超过一日7.5mg（1片）。 　　 本品每日最大建议剂量为15mg(2片)。 　　 儿童适用的剂量尚未确定，目前只限于成人使用。 不良反应 根据国外研究资料报道，以下罗列的不良反应系在本品给药后发生，然而他们的发生频率是根据临床实验记录结果，而无论与本品用药是否有因果关系。这些信息是基于对3750个病人进行的超过18个月的临床实验得到的，病人每日口服本品剂量为7.5或15毫克。（治疗用药的平均时间为127天）。 1、胃肠道：频率超过1％：消化不良、恶心、呕吐、腹痛、便秘、胀气、腹泻。频率介于0.1％和1％之间：短暂的肝功能指标异常（如转氨酶或胆红素升高）。食道炎、胃十二指肠溃疡，隐伏或肉眼可见的胃肠道出血。频率小于0.1％：胃肠道穿孔，结肠炎。 2、血液：频率超过1％：贫血。介于0.1％和1％之间：血细胞计数失调，包括白细胞分类计数，白细胞减少和血小板减少，同时使用潜在的骨髓毒性药物，特别是氨甲喋呤，是导致出现血细胞减少的一个因素。 3、皮肤：频率超过1％：瘙样、皮疹。介于0.1％和1％之间：口炎、寻麻疹。少于0.1％：感光过敏。 　　 4 、呼吸道：频率少于0.1％：已有报道在使用阿斯匹林或其他NSAID，包括本品之后有个体出现急性哮喘。 　　 5、中枢神经系统：频率多于1％：轻微头晕、头痛。介于0.1％和1％：眩晕、耳鸣、嗜睡。 　　 6、心血管：频率多于1％：水肿。介于0.1％和1％之间：血压升高、心悸、潮红。 　　 7、泌尿系统：介于0.1％和1％之间：肾功能指标异常（血清肌酐和／或血清尿素升高）。 禁忌 以下情况禁用：对药物活性成分美洛昔康或其赋形剂已知过敏者。与乙酰水杨酸和其他NSAID可能会有交叉过敏反应。对使用乙酰水杨酸或其他NSAID后出现哮喘、鼻腔息肉、血管水肿或寻麻疹等症状的病人不宜使用本品。活动性消化性溃疡，严重肝功能不全者，非透析严重肾功能不全者，儿童和年龄小于15岁的青少年，孕妇或哺乳者。 孕妇及哺乳期妇女用药 虽然在临床前的试验中没有发现致畸作用，但本品不应用于孕妇和哺乳者。 　　 儿童用药 儿童的适用剂量尚未确定，儿童和年龄小于15岁的青少年禁用。 　　 老年用药 对可能有肝、肾及心功能不全的老年患者应慎用。 药物过量：因为没有已知的解毒药，所以在过剂量情况时应采取胃排空及支持疗法。有临床试验表明消胆胺可促进本品的排泄。 贮藏：遮光、密封保存。放在儿童伸手不及处。 BOXED WARNING(What is this?) Warning Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. See Contraindications, Warnings and Precautions for detailed information. SPL UNCLASSIFIED SECTION (equivalent to 0.05 mg per drop) NADA 141-213, Approved by FDA Non-steroidal anti-inflammatory drug for oral use in dogs only Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Description: Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class. Each milliliter of Metacam Oral Suspension contains meloxicam equivalent to 1.5 milligrams and sodium benzoate (1.5 milligrams) as a preservative. The chemical name for Meloxicam is 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide. The formulation is a yellowish viscous suspension with the odor of honey Indications: Metacam Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs. Dosage and Administration: Always provide client information sheet with prescription. Carefully consider the potential benefits and risk of Metacam and other treatment options before deciding to use Metacam. Use the lowest effective dose for the shortest duration consistent with individual response. Metacam Oral Suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day 1, Metacam Oral Suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/kg). The syringe is calibrated to deliver the daily maintenance dose in pounds. Directions for Administration: Dogs under 10 pounds (4.5 kg) Shake well before use, then remove cap. Particular care should be given with regard to the accuracy of dosing. To prevent accidental overdosing of small dogs, administer drops on food only, never directly into the mouth. Carefully measure suspension onto food to assure that the correct dose is given before presentation of the food to the dog. The syringe provided with the meloxicam concentration of 1.5 mg/mL cannot be used to measure doses for dogs weighing less than 5 lbs (2.3 kg) For dogs less than 5 lbs (2.3 kg), Metacam Oral Suspension can be given using the dropper bottle: one drop for each pound of body weight for the 1.5 mg/mL concentration (two drops for each kilogram of body weight), dropped directly onto the food. For dogs between 5 - 10 pounds, Metacam Oral Suspension can be given by drops or by using the measuring syringe provided in the package (see dosing procedure below). The syringe fits on to the bottle and has a scale beginning at 5 lbs, designed to deliver the daily maintenance dose (0.05 mg/lb or 0.1 mg/kg). When using the syringe, the dog’s weight should be rounded down to the nearest 5 pound increment. Replace and tighten cap after use. Dogs over 10 pounds (4.5 kg) Shake well before use then remove cap. Metacam Oral Suspension may be either mixed with food or placed directly into the mouth. Particular care should be given with regard to the accuracy of dosing. Metacam Oral Suspension can be given using the measuring syringe provided in the package (see dosing procedure below). The syringe fits on to the bottle and has a scale in pounds designed to deliver the daily maintenance dose (0.05 mg/lb or 0.1 mg/kg). When using the syringe, the dog’s weight should be rounded down to the nearest 5 pound increment. Alternatively, Metacam Oral Suspension can be given using the dropper bottle: one drop for each pound of body weight for the 1.5 mg/mL concentration (two drops for each kilogram of body weight). Replace and tighten cap after use. Contraindications: Dogs with known hypersensitivity to meloxicam should not receive Metacam Oral Suspension. Do not use Metacam Oral Suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats. Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For oral use in dogs only. As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration. Owner should be advised to observe their dog for signs of potential drug toxicity and be given a client information sheet about Metacam. Precautions: The safe use of Metacam Oral Suspension in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating dogs has not been evaluated. Meloxicam is not recommended for use in dogs with bleeding disorders, as safety has not been established in dogs with these disorders. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. If additional pain medication is needed after administration of the total daily dose of Metacam Oral Suspension, a non-NSAID or non-corticosteroid class of analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from corticosteroid use or from one NSAID to another in dogs. The use of concomitantly protein-bound drugs with Metacam Oral Suspension has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of Metacam Oral Suspension has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy. Adverse Reactions: Field safety was evaluated in 306 dogs. Based on the results of two studies, GI abnormalities (vomiting, soft stools, diarrhea, and inappetence) were the most common adverse reactions associated with the administration of meloxicam. The following table lists adverse reactions and the numbers of dogs that experienced them during the studies. Dogs may have experienced more than one episode of the adverse reaction during the study. In foreign suspected adverse drug reaction (SADR) reporting over a 9 year period, incidences of adverse reactions related to meloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog), nursing puppy lethargy (1 dog), and pyoderma (1 dog). Post-Approval Experience (Rev. 2010): The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The following adverse events are listed in decreasing order of frequency by body system. Gastrointestinal: vomiting, anorexia, diarrhea, melena, gastrointestinal ulceration Urinary: azotemia, elevated creatinine, renal failure Neurological/Behavioral: lethargy, depression Hepatic: elevated liver enzymes Dermatologic: pruritus Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with use of meloxicam in cats. To report suspected adverse events, for technical assistance or to obtain a copy of the MSDS, contact Boehringer Ingelheim Vetmedica, Inc. at 1-866-METACAM (1-866-638-2226). For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth. Information for Dog Owners: Metacam, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include vomiting, diarrhea, decreased appetite, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes. Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death (see Adverse Reactions). Owners should be advised to discontinue Metacam and contact their veterinarian immediately if signs of intolerance are observed. The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow up for all dogs during administration of any NSAID. Clinical Pharmacology: Meloxicam has nearly 100% bioavailability when administered orally with food. The terminal elimination half life after a single dose is estimated to be approximately 24 hrs (+/-30%) regardless of route of administration. There is no evidence of statistically significant gender differences in drug pharmacokinetics. Drug bioavailability, volume of distribution, and total systemic clearance remain constant up to 5 times the recommended dose for use in dogs. However, there is some evidence of enhanced drug accumulation and terminal elimination half life prolongation when dogs are dosed for 45 days or longer. Peak drug concentrations can be expected to occur within about 7.5 hrs after oral administration. Corresponding peak concentration is approximately 0.464 mcg/mL following a 0.2 mg/kg oral dose. The drug is 97% bound to canine plasma proteins. Effectiveness: The effectiveness of meloxicam was demonstrated in two field studies involving a total of 277 dogs representing various breeds, between six months and sixteen years of age, all diagnosed with osteoarthritis. Both of the placebo-controlled, masked studies were conducted for 14 days. All dogs received 0.2 mg/kg on day 1. All dogs were maintained on 0.1 mg/kg oral meloxicam from days 2 through 14 of both studies. Parameters evaluated by veterinarians included lameness, weight-bearing, pain on palpation, and overall improvement. Parameters assessed by owners included mobility, ability to rise, limping, and overall improvement. In the first field study (n=109), dogs showed clinical improvement with statistical significance after 14 days of meloxicam treatment for all parameters. In the second field study (n=48), dogs receiving meloxicam showed a clinical improvement after 14 days of therapy for all parameters; however, statistical significance was demonstrated only for the overall investigator evaluation on day 7, and for the owner evaluation on day 14. Palatability: Metacam Oral Suspension was accepted by 100% of the dogs when veterinarians administered the initial dose into the mouth. Metacam Oral Suspension was accepted by 90% of the dogs (123/136) when administered by owners. Problems associated with administration included refusal of food, resistance to swallowing and salivation. Safety: Six Week Study In a six week target animal safety study, meloxicam was administered orally at 1, 3, and 5X the recommended dose with no significant clinical adverse reactions. Animals in all dose groups (control, 1, 3 and 5X the recommended dose) exhibited some gastrointestinal distress (diarrhea and vomiting). No treatment-related changes were observed in hematological, blood chemistry, urinalysis, clotting time, or buccal mucosal bleeding times. Necropsy results included stomach mucosal petechiae in one control dog, two dogs at the 3X and one dog at the 5X dose. Other macroscopic changes included areas of congestion or depression of the mucosa of the jejunum or ileum in three dogs at the 1X dose and in two dogs at the 5X dose. Similar changes were also seen in two dogs in the control group. There were no macroscopic small intestinal lesions observed in dogs receiving the 3X dose. Renal enlargement was reported during the necropsy of two dogs receiving the 3X and two receiving the 5X dose. Microscopic examination of the kidneys revealed minimal degeneration or slight necrosis at the tip of the papilla in three dogs at the 5X dose. Microscopic examination of the stomach showed inflammatory mucosal lesions, epithelial regenerative hyperplasia or atrophy, and submucosal gland inflammation in two dogs at the recommended dose, three dogs at the 3X and four dogs at the 5X dose. Small intestinal microscopic changes included minimal focal mucosal erosion affecting the villi, and were sometimes associated with mucosal congestion. These lesions were observed in the ileum of one control dog and in the jejunum of one dog at the recommended dose and two dogs at the 5X dose. Six Month Study In a six month target animal safety study, meloxicam was administered orally at 1, 3, and 5X the recommended dose with no significant clinical adverse reactions. All animals in all dose groups (controls, 1, 3, and 5X the recommended dose) exhibited some gastrointestinal distress (diarrhea and vomiting). Treatment related changes seen in hematology and chemistry included decreased red blood cell counts in seven of 24 dogs (four 3X and three 5X dogs), decreased hematocrit in 18 of 24 dogs (including three control dogs), dose related neutrophilia in one 1X, two 3X and three 5X dogs, evidence of regenerative anemia in two 3X and one 5X dog. Also noted were increased BUN in two 5X dogs and decreased albumin in one 5X dog. Endoscopic changes consisted of reddening of the gastric mucosal surface covering less than 25% of the surface area. This was seen in three dogs at the recommended dose, three dogs at the 3X dose and two dogs at the 5X dose. Two control dogs exhibited reddening in conjunction with ulceration of the mucosa covering less than 25% of the surface area. Gross gastrointestinal necropsy results observed included mild discoloration of the stomach or duodenum in one dog at the 3X and in one dog at the 5X dose. Multifocal pinpoint red foci were observed in the gastric fundic mucosa in one dog at the recommended dose, and in one dog at the 5X dose. No macroscopic or microscopic renal changes were observed in any dogs receiving meloxicam in this six month study. Microscopic gastrointestinal findings were limited to one dog at the recommended dose, and two dogs at the 3X dose. Mild inflammatory mucosal infiltrate was observed in the duodenum of one dog at the recommended dose. Mild congestion of the fundic mucosa and mild myositis of the outer mural musculature of the stomach were observed in two dogs receiving the 3X dose. How Supplied: Metacam Oral Suspension 1.5 mg/mL: 10, 32, 100 and 180 mL dropper bottles with measuring syringe. Storage: Store at controlled room temperature, 68 – 77°F (20 -25°C). Excursions permitted between 59°F and 86°F (15°C and 30°C). Brief exposure to temperature up to 104°F (40°C) may be tolerated provided the mean kinetic temperature does not exceed 77°F (25°C); however such exposure should be minimized. -------------------------------------------------- 注：以下产品不同规格和不同价格，购买以咨询为准！ -------------------------------------------------- 产地国家: 美国 原产地英文商品名: METACAM ORAL SUSP 1.5mg/ml 32mls/bottle 原产地英文药品名: MELOXICAM 中文参考商品译名: METACAM口服混悬剂 1.5毫克/毫升 32毫升/瓶 中文参考药品译名: 美洛昔康 中文参考化合物名称: 4-羟基-2-甲基-N-(5-甲基-1,3-噻唑-2-基)-2H-1,2-苯并噻嗪-3-羧酸乙酯 1,1-二氧化物 生产厂家中文参考译名: 勃林格殷格翰 生产厂家英文名: BOEHRINGER INGELHEIM ------------------------------------------------ 产地国家: 美国 原产地英文商品名: METACAM ORAL SUSP 1.5mg/ml 100mls/bottle 原产地英文药品名: MELOXICAM 中文参考商品译名: METACAM口服混悬剂 1.5毫克/毫升 100毫升/瓶 中文参考药品译名: 美洛昔康 中文参考化合物名称: 4-羟基-2-甲基-N-(5-甲基-1,3-噻唑-2-基)-2H-1,2-苯并噻嗪-3-羧酸乙酯 1,1-二氧化物 生产厂家中文参考译名: 勃林格殷格翰 生产厂家英文名: BOEHRINGER INGELHEIM